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Non-seminomatous germ cell tumours (NSGCTs) represent
approximately 40% of all testicular germ cell tumours that occur
in the adult testis. These tumours are the most commonly diag-
nosed malignancies in young men and account for up to 1 in 7
deaths in males aged between 15 and 45 years (Bergstrom et al,
1996). Although these tumours are readily resected and, unlike
other solid malignancies, respond well to adjuvant therapies up to
one-third of patients with advanced disease fail to respond to treat-
ment and consequently die from these tumours (Toner and Motzer,
1998; Benedetto, 1999). 
To date, no reproducible model for NSGCTs has been
described. This has been identified as a potential obstacle to
further investigations of the underlying pathogenesis of these
tumours (Looijenga and Oosterhuis, 1999). Here, we report the
establishment of an orthotopic xenograft model of human
NSGCT in mouse testis that successfully reproduces many of the
elements observed in the human disease. The clinical relevance
of this model makes it suitable not only for research into the
underlying biomolecular processes of this disease but also in
further refining the current strategies used in treating patients
diagnosed with NSGCT. 
MATERIALS AND METHODS 
Human NSGCT cell culture 
The NTera-2 clone 13 cell line (Thompson et al, 1984) was cloned
from the original Tera-2 cell line initially derived from the
pulmonary metastasis of a 22-year-old male Caucasian patient
(Fogh et al, 1977). The GCT 27 C-4 embryonal carcinoma cell line
was isolated from a malignant primary testicular teratoma (Pera 
et al, 1987). Both cell lines were maintained in a mixture of MEM-
alpha medium and HAMS F12 1:1 supplemented with 10% fetal
bovine serum, 50 µ g mL–1 penicillin, 100 µ g mL–1 streptomycin,
2.5% HEPES with 15 mL L–1 0.833% sodium hydroxide. 
Experimental animals 
Male SCID mice were purchased at 6–7 weeks of age from the
Walter and Eliza Hall Institute Breeding Facility, Melbourne,
Australia and housed in a temperature-controlled, specific
pathogen-free room (23° C, 12h light–dark regime) with free
access to water and a standard diet (Norco, Lismore, NSW,
Australia). Tumour cells were implanted when the mice were 8
weeks of age. The study was approved by the Group 5 Animal
Experimental Ethics Committee of the University of Queensland
and performed according to NHMRC Guidelines (AEEC
Approval Number SURG/394/98, SURG/569/99). 
Xenograft model 
NSGCT tumour cells were implanted by injection in the exterior-
ized left testis of anaesthetized mice (1 × 106 viable cells in
0.25 mL PBS). Mice were culled when the apparent size of the
tumour approached 1 cm3. The testes, viscera, retroperitoneal
lymph nodes, heart, lungs and brain were harvested, weighed and
preserved for histological analysis. Tumour burden was defined as
the weight of the tumour-affected testis expressed as a percentage
of the animal’s total body weight. 
Histology 
Tissues taken for histological study were fixed in 10% buffered
formalin for a minimum of 24 hours. The organs were then
embedded in paraffin and sectioned. Sections were routinely
processed and stained with haematoxylin and eosin. 4 µ m thick
sections were immunostained with antibodies against CD30
(DAKO, 1/30 dilution), S100 (DAKO, 1/4000 dilution), GFAP
(DAKO, 1/7 dilution), AE1/AE3 (Roche, 1/600 dilution), CAM
5.2 (Becton Dickinson, 1/20 dilution) and PLAP (DAKO, 1/100
dilution). The peroxidase-antiperoxidase method was used to
detect specific antibody binding. 
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Xenograft model of human NSGCT 
The requirements for a successful model were met by implanting 
1 × 106 viable NTera-2 C-13 cells in the left testis of male SCID
mice. Tumours developed in all mice and approached the 1 cm3
size end point (less than 5% of host animal’s normal total body
weight) within 4 weeks. Post-mortem examination of these mice
revealed the presence of metastases in sites consistent with
NSGCT progression in human patients (see below and Discus-
sion). Repeated use of this model has demonstrated the repro-
ducibility of this technique (100% occurrence of primary tumours,
mean tumour burden at 4 weeks: 3.68 ± 0.23%, n = 20). 
The GCT 27 C-4 cell line did not prove to be as suitable for
establishment of an animal model of human NSGCT. Primary
tumours developed over a longer time period (6–7 weeks) and
were less consistent in size and appearance, although the pattern of
metastasis was identical to that observed with the NTera-2 C-13
cell line. 
Physical features of the NTera-2 C-13 model of NSGCT 
During the 4-week period of tumour development, the mice exhib-
ited no symptoms or signs of clinical illness apart from a visible or
palpable lump in the lower abdomen or scrotum. The rapid growth
of the tumours was externally visible, with lumps apparent in the
scrotum and lower perineum. As these tumours increased in size,
they generally moved higher into the abdomen and post mortem,
were located in the groin adjacent to the bladder. 
Macroscopically, the primary tumours were large, ovoid 
and mobile in the lower abdomen, involving the entire testis
(Figure 1). The tumours remained discrete without any evidence of
malignant adhesion to adjacent structures. There was no visible
evidence of ascites or seeding of tumour cells in the abdomen and
no obvious nodules in the viscera or lungs. Musculoskeletal
structures appeared macroscopically normal. Visible secondary
tumours were evident in the retroperitoneal lymph nodes in the left
renal hilar lymph region. 
Histology of the NTera-2 C-13 model of NSGCT 
Histological examination of the testicular tumours showed a
poorly differentiated malignancy composed of sheets of tumour
cells surrounding intact seminiferous tubules (Figure 2A). The
cells had large vesicular nuclei with clumped chromatin, one or
more large nucleoli, and indistinct cytoplasm. There was marked
overlapping of nuclei and cell crowding. A high mitotic and apop-
totic rate was identified. In other areas there was evidence of
neuroepithelial differentiation with obvious rosette formation.
Focally the tumour cells were arranged in an eosinophilic fibrillary
background resembling glial differentiation. Immunoperoxidase
stains revealed focal positive staining for CD30 in the large cell
areas with patchy weak staining for CAM 5.2 (data not shown).
The background glial areas were positive for S100 and GFAP and
there was no positive staining for PLAP (data not shown). 
These features are consistent with human NSGCT, with diag-
nostic characteristics of both embryonal carcinoma and immature
teratoma (teratocarcinoma). Histological examination of other
organs revealed deposits of histologically identical tumour in
numerous sites in all animals. Tumour was identified in liver
(Figure 2B) and lung (Figure 2C). Retroperitoneal soft tissue
deposits were evident and focally these abutted the capsule of the
kidney. Tumour was seen clearly within an endothelial lined
lymphovascular space within the retroperitoneal tissues (Figure
2D). Metastatic deposits were also identified within the adrenal
cortex and pancreas (data not shown). No metastases were identi-
fied within the kidney itself or within heart, brain or spleen. 
DISCUSSION 
In the past, tumour models were based on tumours that developed
spontaneously in certain species, or as a result of specific genetic
abnormalities that arose either from breeding programmes or the
deliberate alteration of certain genes (transgenic or ‘knock-out’
lines). Although valuable in studies of developmental processes,
these models have not proved as useful for cancer research.
Testicular germ cell tumours are particularly difficult to study
using these approaches as human tumours differ markedly from
spontaneous testicular tumours observed in mice (Walt et al,
1993). 
Xenograft models using single-cell suspensions of tumour cells
provide a distinct advantage in that cells may be studied and
manipulated in vitro, complementing research performed in vivo.
A number of studies have used heterotopic xenografts (most often
generated by implanting tumour tissue or cells subcutaneously) to
study the growth rates of tumours, the efficacy of therapeutic
compounds and/or the biological properties of the tumour in vivo.
Whilst these tumours are seen to grow readily and are easily moni-
tored, these models rarely exhibit clinically important features
such as metastasis. Xenograft tumours are more likely to develop
in a clinically relevant way and metastasize when orthotopically
implanted, where environmental conditions more accurately
reflect many of the tumour–host cell interactions that take place
during naturally occurring tumour development and progression
(Fidler, 1990). Thus, the use of orthotopic xenografts is critical in
generating clinically representative models of human disease. 
Recently, Konaka et al (1999) described the first orthotopic
xenograft model of human testicular germ cell tumour, where
wedges of heterotopically xenografted human seminoma were
implanted orthotopically in the testes of SCID mice. This model
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Figure 1 Typical macroscopic appearance of a male SCID mouse 4 weeks
after inoculation of the left testis with 1 × 106 viable NTera-2 C-13 cells. The
tumour-affected left testis (LT) and contralateral normal testis (RT) are shown
circled in black. The left renal hilar lymphatic tissue (LHL) is shown circled in
white produced clinically relevant metastases and therefore represents a
significant advance in the study of seminomatous tumours.
However, there are some limitations to its usefulness in certain
experimental circumstances and it may not be applicable for
studying the more heterogeneous NSGCT. 
We have developed a versatile orthotopic xenograft model
where NSGCTs develop from cell lines rather than from grafted
tumour tissue. The use of cell lines provides a number of distinct
advantages. Whereas a clinical specimen from a human patient can
only be used to establish a model once, cell lines allow repeated
experiments using a reproducible model. The ability to culture and
store cells for extended periods of time allows greater flexibility in
experimental planning and experiments are not dependent on the
availability of suitable patient tissue. Further, the use of cell lines
obviates the necessity to maintain tumours by repeated subcuta-
neous implantation from mouse to mouse. An added benefit is that
implantation of tumour cells by injection of single cell suspension
is an easy technique to perform, increasing the reproducibility of
the model and its application. More importantly, cell lines can be
manipulated in vitro, allowing a wide range of investigations to be
carried out, including research into the biology of particular genes.
Some have argued that injections of cell suspensions do not result
in as extensive metastasis as implantation of whole tumour frag-
ments (An et al, 1999; Hoffman, 1999). Our experience with both
the NSGCT model described here and a similar model of human
renal cell carcinoma (RCC) also established in our laboratory (Hii
et al, 1998) does not agree. In both cases, the rate of development
and the pattern and extent of metastasis has been comparable if not
superior to fragment implantation models of similar tumours. To
compare, the seminoma model described by Konaka et al demon-
strated obvious primary tumours and lymph node metastasis 11
weeks after implantation of tumour fragments, but pulmonary and
visceral metastasis was not histologically evident. Our NSGCT
model, using cell suspensions, repeatedly exhibits large primary
tumours and lymph node metastases and histologically visible
metastases in the lungs and various other organs. Similarly, our
RCC model using cell suspensions yields large primary tumours
and macroscopically visible pulmonary metastases within 35 days,
whereas the tumour fragment model described by An et al, was
reported to require 40 days. We therefore maintain that use of
single cell suspensions offers many advantages and does not
necessarily reduce the efficacy or relevance of an orthotopic
xenograft model. 
In summary, we have established an orthotopic xenograft model
of human NSGCT that is easily performed, reproducible and able
to generate rapid results that are clinically relevant. The primary
tumours bear many characteristics typical of NSGCT as seen in
human patients and are histopathologically recognizable as typical
NSGCTs. To the authors’ knowledge, this model is the first of its
kind to be described and will be invaluable for future studies of
factors that influence the development of human NSGCT as well
as the development of new therapeutic strategies. 
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Figure 2 (A) Malignant tumour surrounding native seminiferous tubules
(original magnification × 100). (B) Tumour deposit within the hepatic
parenchyma (original magnification × 250). (C) Pulmonary deposit of tumour
(original magnification × 250). (D) Lymphovascular space involvement by
tumour (original magnification × 250) An animal model of human testicular cancer 611
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